Unicorn Capital Partners
1 Feb 2022 г. • 4 min
Unicorn Capital Partners, RDIF and AstraZeneca invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant arterial hypertension
February 1, 2022, Moscow. Unicorn Capital Partners, a biotech-specialized VC fund, based in Moscow, Russia, together with AstraZeneca and the Russian Direct Investment Fund (RDIF) as co-investors, have entered into an investment agreement with Target Medicals,. The financing size is not disclosed, but it should get the company to completion of preclinical proof-of-concept studies, with a purpose to nominate a drug candidate for further clinical trials.